Vivos Announces Strong Momentum and Revenue Growth Prospects in 2024
Vivos Therapeutics, Inc. (the “company” or “Vivos”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of.
Industry News
Industry News
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
Vivos Therapeutics, Inc. (“Vivos” or the “company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial.
Industry News
Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution
Vivos Therapeutics, Inc., a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate.
Industry News
Vivos Therapeutics Announces Formation of New Medical Consortium to Advance the Company’s Technology for Obstructive Sleep Apnea
Drs. Clete Kushida of Stanford and Cecilia Wu of University of Alberta to lead a team of prominent, multi-disciplinary medical doctors guiding research.
Industry News
FDA Grants 510(k) Market Clearance to Vivos Therapeutics’ mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea
Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities.
Industry News
Vivos Therapeutics Opens State of the Art International Training Center In Denver
Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities.
Industry News
Vivos Therapeutics Establishes Clinical Advisory Board
Vivos Therapeutics has established a clinical advisory board to drive adoption and growth of its treatments for obstructive sleep apnea, which impacts a.
